Abstract：【Objective】To investigate the clinical effect of interleukin-6 (IL-6) receptor antagonist in the treatment of patients with ventricular arrhythmia after myocardial infarction.【Methods】A total of 100 patients with ventricular arrhythmia after myocardial infarction treated in our hospital from June 2022 to June 2024 were selected and divided into the observation group (treated with IL-6 receptor antagonist tocilizumab injection) and the control group (treated with conventional succinate metoprolol sustained-release tablets) according to different treatment methods, with 50 cases in each group. The total treatment efficiency, total satisfaction, quality of life, cardiac function indexes, and inflammatory factor levels were compared between the two groups. 【Results】The total treatment efficiency, satisfaction, and quality of life scores of the observation group were significantly higher than those of the control group (P<0.05); the cardiac function indexes of the observation group were better than those of the control group (P<0.05); the level of matrix metalloproteinase-9 (MMP-9) in the observation group was higher than that in the control group, while the levels of tumor necrosis factor-α (TNF-α), IL-6, and high-sensitivity C-reactive protein (hs-CRP) were lower than those in the control group, and the differences were statistically significant (P<0.05). 【Conclusion】The treatment of patients with ventricular arrhythmia after myocardial infarction with the IL-6 receptor antagonist tocilizumab injection has a significant effect, which can improve patient satisfaction, quality of life and cardiac function, and reduce the levels of inflammatory factors.
高苏莉, 郑辉, 李耀. IL-6受体拮抗剂治疗心肌梗死后室性心律失常患者的临床效果*[J]. 医学临床研究, 2025, 42(6): 913-915.
GAO Suli, ZHENG Hui, LI Yao. Clinical Effect of IL-6 Receptor Antagonist in the Treatment of Patients with Ventricular Arrhythmia after Myocardial Infarction. JOURNAL OF CLINICAL RESEARCH, 2025, 42(6): 913-915.
2025, Vol. 42 
